MedImmune And National Institutes Of Health Begin Clinical Testing Of A Live, Attenuated Intranasal Vaccine Against An H5N1 Avian Influenza Virus

MedImmune, Inc.(Nasdaq: MEDI) announced today that the National Institutes of Health (NIH)has begun enrolling participants in a Phase 1 study of an intranasal H5N1influenza vaccine candidate based on the company´s live, attenuated vaccinetechnology. [click link for full article]